SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Pfizer - Quaterly Results

19 May 2025 Evaluate
The revenue zoomed 8.28% to Rs. 5919.10 millions for the quarter ended March 2025 as compared to Rs. 5466.30 millions during the corresponding quarter last year.Profit after tax for the quarter ended March 2025 reported a huge growth of 85.03% to Rs. 3309.40  millions from Rs. 1788.60 millions.The company reported a good operating profit of 2720.80 millions compared to 2645.60 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202503 202403 % Var 202503 202403 % Var 202503 202403 % Var
Sales 5919.10 5466.30 8.28 22813.50 21931.70 4.02 22813.50 21931.70 4.02
Other Income 445.80 751.30 -40.66 1722.50 1805.10 -4.58 1722.50 1805.10 -4.58
PBIDT 2720.80 2645.60 2.84 9124.80 8158.10 11.85 9124.80 8158.10 11.85
Interest 26.90 69.50 -61.29 84.10 154.10 -45.43 84.10 154.10 -45.43
PBDT 4422.00 2576.10 71.65 10768.80 8083.50 33.22 10768.80 8083.50 33.22
Depreciation 164.00 137.50 19.27 607.90 622.80 -2.39 607.90 622.80 -2.39
PBT 4258.00 2438.60 74.61 10160.90 7460.70 36.19 10160.90 7460.70 36.19
TAX 948.60 650.00 45.94 2484.90 1947.40 27.60 2484.90 1947.40 27.60
Deferred Tax -42.00 163.10 -125.75 -156.10 361.10 -143.23 -156.10 361.10 -143.23
PAT 3309.40 1788.60 85.03 7676.00 5513.30 39.23 7676.00 5513.30 39.23
Equity 457.50 457.50 0.00 457.50 457.50 0.00 457.50 457.50 0.00
PBIDTM(%) 45.97 48.40 -5.02 40.00 37.20 7.53 40.00 37.20 7.53

Pfizer Share Price

4815.00 3.95 (0.08%)
11-May-2026 09:28 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1845.00
Dr. Reddys Lab 1281.55
Cipla 1339.50
Zydus Lifesciences 932.80
Lupin 2282.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×